Leading the way to safer medication
 Crosscheck  Recommender

Alirocumab

Description

Alirocumab is a fully human IgG1 monoclonal antibody that binds with high affinity and specificity to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. LDLR is the primary receptor that clears circulating LDL, therefore the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-C. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.

Medicine classification

ATC Code
Title
Class
C10AX14
Alirocumab
C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AX Other lipid modifying agents

Medicines

Drug
Countries

Austria Canada Cyprus France Lithuania

Product monographs

Monograph
Type
Country
PRALUENT Solution for injection
MPI, EU: SmPC